Acrivon therapeutics to host corporate r&d event highlighting ap3 and pipeline progress, including ongoing prospective validation of acr-368 oncosignature with initial phase 2 data for acr-368, and preclinical progress for acr-2316

Watertown, mass., april 16, 2024 (globe newswire) -- acrivon therapeutics, inc. (“acrivon” or “acrivon therapeutics”) (nasdaq: acrv), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, acrivon predictive precision proteomics (ap3), today announced it will be holding a virtual corporate r&d event on april 24th, 2024 from 4:15 p.m. to 5:30 p.m. et. the agenda will feature presentations by acrivon's leadership team followed by an interactive q&a session.
ACRV Ratings Summary
ACRV Quant Ranking